高血压和动脉粥样硬化患者基质金属蛋白酶-9水平的检测及临床意义

Study on serum levels of Matrix Metallopro-teinases-9 in the patients of hypertension and atherosclerosis

目的探讨高血压和动脉粥样硬化患者中基质金属蛋白酶9(MMP9)的水平及临床意义。方法采用ELISA方法对高血压(208例)和动脉粥样硬化(48例)患者、健康对照者(50例)血清MMP9水平进行测定。结果高血压患者、动脉粥样硬化患者、对照组MMP9水平分别为(368.19±48.83)ng/ml、(544.33±50.71)ng/ml、(255.82±25.10)ng/ml,高血压患者血清MMP9水平与动脉粥样硬化患者相比有极显著性差异(P<0.01),且两组与对照组比均有极显著性差异(P<0.01)。结论血清MMP9水平可作为高血压患者向动脉粥样硬化发展的预警指标。

Objective To study clinic significance on determination matrix metallopro-teinases-9(MMP-9) in the patients of hypertension and atherosclerosis. Methods Using ELISA method detective serum MMP-9 in the control group (50cases) and the patients of hypertension (208 cases) and atherosclerosis (48 cases). Results In the control group and patients of hypertension and atherosclerosis, their levels of MMP-9 are ( 255.82 ± 25.10 ) ng/ml,( 368.19 ± 48.83 ) ng/ml and ( 544.33 ± 50.71 ) ng/ml respectively, there are significantly different between patients of hypertension and atherosclerosis and the control group ( P < 0.01 ), MMP-9 levels of atherosclerosis patients are markedly higher than that of hypertension ones ( P <0.01). Conclusion MMP-9 may be a vealuable indictor for preventing hypertensive become atherosclerosis.